Google
IMVT 株価分析 — IMMUNOVANT INC (Healthcare >> Biotechnology)
IMVT に関するよくある質問
IMVTのROE（自己資本利益率）は？
IMMUNOVANT INCのROEは-59.30%です。
IMVTの配当利回りは？
IMMUNOVANT INCの配当利回りは0.00%です。
IMVTの品質スコア（Quality Score）は？
当社のAIはIMVTの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
IMVTは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
IMVTはどのセクターに属しますか？
IMMUNOVANT INCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
IMVT AI Analysis Summary
Our AI summary for IMVT: IMMUNOVANT INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -59.30%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 38.62
Price
-0.86
(-2.18%)
Day Change
|
|
|---|
IMVT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 38.62 |
| PBV / Sector |
9.23 / 5.20
|
| Earning Per Share | -2.77 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
38.36 M
GREAT
|
| Average 1W Daily Value |
36.52 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:00 |
| Symbol | IMVT |
| Name | IMMUNOVANT INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 205.31 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 7,867.25 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1000 Park Forty Plaza, Durham, NC, United States, 27713
Phone: 917 410 3120
Website: https://immunovant.com
Employees: 315
Sector: Healthcare >> Biotechnology
Description: Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
